Prostamax (KEDP)

KEDP Tetrapeptide | Prostate Bioregulator

Weight: 473 Da
Half-life: Not established
Chain: 4 amino acids
4 studies
2020 latest
Moderate Research
Dose 10-20mg daily
Frequency Daily for 10-20 days per cycle
Cycle 10-20 days
Storage Capsules at room temperature; reconstituted injectable at 2-8°C refrigerated

Community Research

Join others researching Prostamax — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

Prostamax is a Khavinson bioregulator tetrapeptide (KEDP) with primary repair effects on prostate tissue. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it alters chromatin structure in cells from elderly individuals, promoting deheterochromatinization and potentially reactivating genes repressed during aging. Research in rat models shows reduced prostate inflammation, decreased swelling, and decelerated pathological remodeling associated with prostatitis.

Mechanism of Action

Prostamax works through epigenetic regulation by altering chromatin structure. It increases the frequency of sister chromatid exchanges and Ag-positive nucleolar organizer regions (NORs), while reducing large segments of pericentromeric heterochromatin. These changes promote chromatin decondensation and deheterochromatinization, potentially reactivating genes repressed during aging. The peptide influences heterochromatin arrangements in human lymphocytes and normalizes age-related changes in cellular function.

01 Reduces prostate inflammation
02 Decreases prostatic swelling
03 Reduces vascular congestion (hyperemia)
04 Decreases immune cell infiltration
05 Reduces scarring in prostate tissue
06 Promotes chromatin decondensation
07 Reactivates age-repressed genes
08 Improves lymphocyte function

Molecular Data

Molecular Weight
473 Da
Chain Length
4 amino acids
Type
Tetrapeptide bioregulator
Amino Acid Sequence
One-letter: KEDP
H₂N
K 1
O ‖ C
N
E 2
O ‖ C
N
D 3
O ‖ C
N
P 4
COOH
Lys
1

Lysine

Position 1

Glu
2

Glutamic Acid

Position 2

Asp
3

Aspartic Acid

Position 3

Pro
4

Proline

Position 4

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Research Indications

Prostate Health
Chronic Prostatitis effective

Research shows reduced inflammation and swelling in prostatitis models.

Prostatic Inflammation effective

Mitigates inflammation and immune cell infiltration in prostate tissue.

Prostate Tissue Repair moderate

Decreases scarring and pathological remodeling in prostate.

Anti-Aging
Chromatin Remodeling effective

Promotes deheterochromatinization in elderly cells.

Gene Reactivation moderate

Potentially reactivates genes repressed during aging process.

Lymphocyte Function moderate

Normalizes age-related changes in lymphocyte function.

Dosing Protocols

Available in capsule form for oral administration. Short peptides can be absorbed orally and reach target tissues. Typical protocol involves 10-20 day cycles.

GoalDoseFrequencyRoute
Standard protocol10-20 mgDaily for 10-20 daysOral capsules
Maintenance10 mg2-3 cycles yearlyOral capsules

Interactions

++
Testagen
Complementary male reproductive bioregulators; different tissue targets.
synergistic
++
Epitalon
Often combined in comprehensive anti-aging Khavinson protocols.
synergistic
+
Vilon
Different organ targets; can be used in comprehensive bioregulator protocols.
compatible
+
Crystagen
Part of Khavinson bioregulator family; targets different tissue.
compatible

What to Expect

During cycle
Chromatin remodeling and gene expression changes begin
Post-cycle
Effects persist due to epigenetic changes
Weeks-Months
Prostate function improvements
Long-term
Cumulative benefits with periodic cycles

Side Effects & Safety

Common Side Effects

  • Generally well-tolerated
  • Minimal side effects reported

Stop Signs - Discontinue if:

  • Allergic reactions
  • Unusual urinary symptoms

Contraindications

  • Prostate cancer (consult oncologist)
  • Known hypersensitivity
  • Pregnancy (not applicable)

Quality Checklist

Good Signs

  • White powder or capsules
  • Clear solution if reconstituted
  • Proper packaging and labeling

Warning Signs

  • Unknown source or purity

Bad Signs

  • Discoloration
  • Unusual odor
  • Damaged packaging

References

  • Experimental Studying of Drug Efficiency Prostamax in Therapy of Chronic Aseptic Prostatitis
    Bulletin of Experimental Biology and Medicine (2013)

    Prostamax reduced prostate swelling, inflammation, and scarring in rat prostatitis models.

  • Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects
    Bulletin of Experimental Biology and Medicine (2004)

    KEDP peptide alters chromatin structure, promoting deheterochromatinization in elderly cells.

  • Deheterochromatinization of Chromatin in Old Age Induced by Oligopeptide Bioregulator (Lys-Glu-Asp-Pro)
    Georgian Medical News (2012)

    Prostamax promotes chromatin decondensation and reactivates age-repressed genes.

  • Khavinson Peptide Bioregulators
    Advances in Gerontology (2020)

    Comprehensive review of bioregulator peptides and their epigenetic mechanisms.

Related Peptides

Testagen synergistic

Complementary male reproductive bioregulators; different tissue targets.

Epitalon synergistic

Often combined in comprehensive anti-aging Khavinson protocols.

Vilon compatible

Different organ targets; can be used in comprehensive bioregulator protocols.

Crystagen compatible

Part of Khavinson bioregulator family; targets different tissue.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.